India has a traditional Covid vax

[Manonthestreet]

Import this and I bet your vax rate would improve.

India’s Covaxin COVID-19 vaccine 77.8% effective, Lancet study finds

A new study in The Lancet is offering the first peer-reviewed and published data on the efficacy of Covaxin, a COVID-19 vaccine developed in India. The vaccine was found to be 77.8 percent effective at preventing symptomatic COVID-19 in a large Phase 3 clinical trial.

newatlas.com

 

[sparky]

Covaxin - Wikipedia

en.wikipedia.org

~S~

 

[RodISHI]

China's vax is traditional too. Ask those in the crematoriums how that is working out.

 

[Manonthestreet]

China's vax is traditional too. Ask those in the crematoriums how that is working out.

Which has nothing to do with Indias

 

[RodISHI]

Does "rare blood clots".

Covaxin side effects: What to know about India's COVID-19 vaccine

In this Snapshot feature, we provide an overview of the Covaxin inactivated virus vaccine for COVID-19 and its possible side effects.

www.medicalnewstoday.com

 

[Crepitus]

Import this and I bet your vax rate would improve.

India’s Covaxin COVID-19 vaccine 77.8% effective, Lancet study finds

A new study in The Lancet is offering the first peer-reviewed and published data on the efficacy of Covaxin, a COVID-19 vaccine developed in India. The vaccine was found to be 77.8 percent effective at preventing symptomatic COVID-19 in a large Phase 3 clinical trial.

newatlas.com

J&J does too. Go get your shot.

 

[Manonthestreet]

J&J does too. Go get your shot.

have not heard theirs described that way. Dont need a vax...have immunity

 

[badger2]

There are no entries for alhydroxyquim-II at Pubmed, though ViroVax (Kansas) was funded for adjuvants as early as 2009. So when did Fau Chi first know about this NIH-funded aluminum-based adjuvant in Covaxin? The Wiki page for Covaxin has one reference to alhydroxyquim-II with an identity wall attached to it (ref #9). Ref #10 is the article about Fau Chi and alhydroxyquim-II, that links to Toll-like receptors. This TLR technology should be published. NIH Adjuvant Program funded the adjuvant.

 

[badger2]

Fau Chi’s involvement and knowledge and NIH funding of this Indian vaccine adjuvant links to Yong-zhen Zhang of the Chinese CDC. Mentioned on other USMB threads, links to Hooper’s passages on EC Holmes(www.aidsorigins.com/), Zhang and Holmes co-authored papers together, Zhang linking the same tick that causes fatal Heartland virus in Missouri and Tennessee. This is a good article for initial investigation of vaccines and adjuvants, and points to 2009 influenza. This influenza compares with Fau Chi’s senate testimony of 26 Ap 2012 on influenza and the Tongguan copper miners (ill 25-26 Ap 2012) at the same location from which came SARS-CoV-2’s closest relative:

(2014) TLR7 / Vaccine

From empiricism to rational design: a personal perspective of the evolution of vaccine development - PubMed

Vaccination, which is the most effective medical intervention that has ever been introduced, originated from the observation that individuals who survived a plague or smallpox would not get the disease twice. To mimic the protective effects of natural infection, Jenner - and later Pasteur -...

pubmed.ncbi.nlm.nih.gov

 

[badger2]

Article in post #9 mentions RSV. Covaxin’s adjuvant tech goes back to before SARS-CoV happened in the civet. Readers will run into a paywall to read the article, below. The article mentions thrombopoietin, so has bearing on mRNA vaccines and the thrombocytopenia/rare blood disease thread here at USMB:

2003 Toll-Like Receptors / RSV Fusion Protein / Thrombopoietin

Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus - PubMed

Immunization with native fusion (F) protein from respiratory syncytial virus (RSV) adsorbed to alum adjuvant generates greater than fourfold rises in serum neutralizing antibody titers in approximately 50% of seropositive humans. Using BALB/c mice we demonstrate herein that enhanced...

pubmed.ncbi.nlm.nih.gov